share_log

藥明康德：海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 18 10:32
Summary by Moomoo AI
药明康德（股份代號：2359）於2024年3月18日發布了截至2023年12月31日的募集資金存放與實際使用情況專項報告及審核報告。報告由德勤華永會計師事務所（特殊普通合夥）審核，確認药明康德的募集資金存放與實際使用情況真實反映了公司截至2023年底的資金狀況。药明康德於2018年和2020年分別進行了A股首次公開發行和非公開發行股票，募集到的資金主要用於若干項目的建設與發展。截至2023年底，公司已完成了A股首次公開發行募投項目的整體結項，並將節餘募集資金永久補充流動資金。同時，2020年A股非公開發行募投項目亦已全部實施完畢，並決定將節餘募集資金永久補充公司流動資金。報告指出，药明康德及其子公司不存在使用闲置募集资金暂时补充流动资金的情况，且募集资金的使用及管理均符合相關法規要求，沒有違規使用募集資金的情形。
药明康德（股份代號：2359）於2024年3月18日發布了截至2023年12月31日的募集資金存放與實際使用情況專項報告及審核報告。報告由德勤華永會計師事務所（特殊普通合夥）審核，確認药明康德的募集資金存放與實際使用情況真實反映了公司截至2023年底的資金狀況。药明康德於2018年和2020年分別進行了A股首次公開發行和非公開發行股票，募集到的資金主要用於若干項目的建設與發展。截至2023年底，公司已完成了A股首次公開發行募投項目的整體結項，並將節餘募集資金永久補充流動資金。同時，2020年A股非公開發行募投項目亦已全部實施完畢，並決定將節餘募集資金永久補充公司流動資金。報告指出，药明康德及其子公司不存在使用闲置募集资金暂时补充流动资金的情况，且募集资金的使用及管理均符合相關法規要求，沒有違規使用募集資金的情形。
Ming Kand Pharmaceuticals (stock code: 2359) issued on March 18, 2024 a special report and audit report on the storage and actual use of funds raised as of December 31, 2023. The report, reviewed by Dak Kin Huayong Accounting Firm (Special General Partnership), confirms that the fundraising and actual use of Ming-Kand Pharmaceutical funds are a true reflection of the Company's financial position as of the end of 2023. In 2018 and 2020, Ming Kander conducted an initial public offering and a non-public offering of shares of A-shares. The funds raised were primarily used for the construction and development of certain projects. As of the end of 2023, the Company has completed the overall closing of the A-share Initial Public Offering and will permanently...Show More
Ming Kand Pharmaceuticals (stock code: 2359) issued on March 18, 2024 a special report and audit report on the storage and actual use of funds raised as of December 31, 2023. The report, reviewed by Dak Kin Huayong Accounting Firm (Special General Partnership), confirms that the fundraising and actual use of Ming-Kand Pharmaceutical funds are a true reflection of the Company's financial position as of the end of 2023. In 2018 and 2020, Ming Kander conducted an initial public offering and a non-public offering of shares of A-shares. The funds raised were primarily used for the construction and development of certain projects. As of the end of 2023, the Company has completed the overall closing of the A-share Initial Public Offering and will permanently supplement the remaining raising funds with liquidity. At the same time, the 2020 IPO of A shares has been fully implemented and it has been decided to permanently supplement the Company's liquidity with the remaining funds raised. The report noted that Ming Kund Pharmaceuticals and its subsidiaries did not provide temporary replenishment of liquid funds and that the use and management of the raising funds met the relevant regulatory requirements and that there was no violation of the use of fundraising funds.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more